Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Information | RedChip

Elicio Therapeutics Inc. (NASDAQ: ELTX)


$5.2400
N/A ( +3.97% ) 11.4K

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Market Data


Open


$5.2400

Previous close


$5.2400

Volume


11.4K

Market cap


$56.55M

Day range


$5.0400 - $5.2550

52 week range


$2.9600 - $11.4500

SEC Filings


Form Type Description Pages Date
8-k 8K-related 19 Jul 01, 2024
8-k 8K-related 55 Jun 27, 2024
8-k 8K-related 18 May 24, 2024
8-k 8K-related 19 May 15, 2024
10-q Quarterly Reports 130 May 15, 2024
10-k/a Quarterly Reports 15 Apr 29, 2024
8-k 8K-related 19 Apr 05, 2024
10-k Annual reports 175 Mar 29, 2024
8-k 8K-related 19 Mar 29, 2024
4 Insider transactions 1 Mar 20, 2024

Latest News